Abstract
ObjectivesThe addition of a poly(ADP-ribose) polymerase (PARP) inhibitor as maintenance therapy led to a significant progression-free survival benefit in patients (pts) with newly diagnosed advanced ovarian cancer who were homologous...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have